Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 4/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | UBE2N | P61088 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6697306 | 1.00 | SMN1; SMN2 (0.71) | SMN1; SMN2KDM4EMAPTPOLBNPSR1 | |
| SCHEMBL4580492 | 0.90 | KDM4E (0.82) | SMN1; SMN2KDM4EMAPTPOLBNPSR1 | |
| SCHEMBL9330581 | 0.86 | SMN1; SMN2 (0.74) | SMN1; SMN2KDM4EMAPTPOLBNPSR1 | |
| SCHEMBL31302688 | 0.86 | SMN1; SMN2 (0.74) | SMN1; SMN2KDM4EMAPTPOLBNPSR1 | |
| SCHEMBL5878421 | 0.85 | L3MBTL1 (0.77) | SMN1; SMN2KDM4EPOLBMAPK1RAB9A | |
| SCHEMBL24322808 | 0.85 | L3MBTL1 (0.77) | SMN1; SMN2KDM4EPOLBMAPK1RAB9A | |
| SCHEMBL16392457 | 0.84 | SMN1; SMN2 (0.97) | SMN1; SMN2KDM4EMAPTPOLBMAPK1 | |
| SCHEMBL16370963 | 0.84 | SMN1; SMN2 (0.71) | SMN1; SMN2KDM4EMAPTPOLBNPSR1 | |
| SCHEMBL4579674 | 0.84 | SMN1; SMN2 (0.97) | SMN1; SMN2KDM4EMAPTPOLBMAPK1 | |
| SCHEMBL16371128 | 0.84 | KDM4E (0.77) | SMN1; SMN2KDM4EMAPTPOLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | SMN1; SMN2 4226/4885KDM4E 4426/4885MAPT 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.